zinostatin stimalamer

Zinostatin stimalamer is a **polymer-conjugated derivative of neocarzinostatin**, classified as a small molecule cytotoxic antibiotic used as an anticancer drug[1][3][4]. It consists of one molecule of neocarzinostatin covalently linked to two molecules of poly(styrene-co-maleic acid)[4]. Its primary mechanism is **targeting and binding to DNA within cancer cells, inducing double-strand breaks and inhibiting DNA synthesis**[3][4][9]. This results in potent cytotoxicity against tumor cells and, additionally, may induce host-mediated tumor immune resistance[4]. It has mainly been used for the treatment of **liver cancer (hepatocellular carcinoma), particularly by intra-arterial administration (often with lipiodol)**, and is approved for this indication in certain regions[2][3][5][6][8]. It has also been studied for brain cancer but is not marketed for this indication[3]. The drug was developed based on discoveries at Kumamoto University with participation from multiple Japanese pharmaceutical companies[3].

Brand names

SMANCS

Other names

zinostatin stimalamerNeocarzinostatin, conjugate with styrene maleic acid anhydride copolymerPoly(maleic acid-styrene)neocarzinostatin